⌘K
Loading ticker…
Allogene Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Allogene Therapeutics, Inc. Common Stock (ALLO) has a 3-month relative strength percentile of 24 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 61. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.7%, relative volume 3.09×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
24 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ALLO is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 0.7% / 19.6%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
ALLO is held by 5 ETFs as of Mar 2026. Top owner: XBI at 0.17% weight, $13M notional. Top 3 carry $34M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 0.17% | $13M |
| VTIVanguard Total Stock Market ETF | 0.00% | $12M |
| IWMiShares Russell 2000 ETF | 0.01% | $9M |
| VXFVanguard Extended Market ETF | 0.01% | $5M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $843K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALLO Jan avg: 12.80% median: 16.20% win: 75% σ: 21.38% n: 4 2022-04-12 → 2026-05-29 | ALLO Feb avg: 20.29% median: 23.91% win: 75% σ: 31.13% n: 4 2022-04-12 → 2026-05-29 | ALLO Mar avg: -17.13% median: -17.22% win: 0% σ: 7.76% n: 4 2022-04-12 → 2026-05-29 | ALLO Apr avg: -5.48% median: -1.42% win: 40% σ: 21.23% n: 5 2022-04-12 → 2026-05-29 | ALLO May avg: -9.25% median: -5.03% win: 20% σ: 12.47% n: 5 2022-04-12 → 2026-05-29 | ALLO Jun avg: 7.05% median: -4.38% win: 25% σ: 24.51% n: 4 2022-04-12 → 2026-05-29 (current) | ALLO Jul avg: 12.17% median: 11.36% win: 75% σ: 11.00% n: 4 2022-04-12 → 2026-05-29 | ALLO Aug avg: -8.66% median: -9.34% win: 25% σ: 11.17% n: 4 2022-04-12 → 2026-05-29 | ALLO Sep avg: -5.88% median: -6.02% win: 50% σ: 16.24% n: 4 2022-04-12 → 2026-05-29 | ALLO Oct avg: -6.11% median: -6.69% win: 0% σ: 4.86% n: 4 2022-04-12 → 2026-05-29 | ALLO Nov avg: -1.53% median: -3.60% win: 25% σ: 14.26% n: 4 2022-04-12 → 2026-05-29 | ALLO Dec avg: -4.97% median: -10.14% win: 25% σ: 30.49% n: 4 2022-04-12 → 2026-05-29 |